Key points from article :
Matter Bio, a longevity biotech company, has secured $7 million in seed funding to develop treatments aimed at preserving genomic integrity and extending human lifespan.
The company's approach focuses on counteracting age-related damage to DNA, such as mutations and epigenetic drift, which are considered key drivers of aging.
Matter Bio plans to achieve this through a three-pronged strategy: detecting genomic information loss, correcting mutations, and eliminating irreparably damaged cells.
The company is led by a team of renowned scientists, including George Church, a pioneer in gene editing, and is supported by Lifespan Vision Ventures and other investors.
The funding will be used to advance research into the information theory of aging and initiate a clinical trial targeting solid cancers.
Matter Bio aims to transform the treatment of age-related diseases by restoring genome integrity using cutting-edge gene editing and sequencing technologies.
